Copyright © 2009 Research To Practice. All rights reserved. National Patterns of Care Study October 2009 100 Randomly Selected US-based Medical Oncologists.

Slides:

Advertisements

Similar presentations

Dr Kavita Raj Consultant Haematologist Guys and St Thomas’ Hospital.

Advertisements

HEMATOLOGY WHAT IT IS : Study & measurement of individual elements of Blood. WHAT IT’S COMPOSED OF. SHOW SLIDES FROM PERIPHERAL BLOOD TUTOR CD OR USE PLATE.

Current Treatment Options in MDS Dick Wells MD, DPhil, FRCPC Director, Crashley Myelodysplastic Syndrome Research Laboratory Odette Cancer Centre.

Neel Bhalala (2009) Sofia Medical University. Background  Erythropoiesis-stimulating agents are man-made versions of a natural protein known as erythropoietin.

Linezolid-Induced Anemia in a Patient with Osteomyelitis

MLAB Hematology Keri Brophy-Martinez

EHA highlights News in MDS JULY31, TYR,LEBANON MARCEL MASSOUD, M.D.

Slide 1 of 16 Dose Titration in a Patient with Myelodysplastic Syndromes.

MDS - Diagnosis and Treatments

CLL- Chronic Lymphocytic Leukemia

Myelodysplasia Diagnosis and Treatment Dr Christopher Dalley Consultant Haematologist The Royal Hallamshire Hospital.

Current Treatments in MDS; the Scottish Perspective

Drugs Used in the Treatment of Multiple Myeloma Myeloma Canada National Conference 2011-September-24 Toronto, Ontario Carlo De Angelis, RPh, PharmD Clinical.

Clinical importance and safety of ESAs for patients with Myelodysplastic Syndromes (MDS) Steven D. Gore, MD Associate Professor of Oncology Sidney Kimmel.

Michael Dickinson, Haematologist

History 2: 70 year old female

Managing the Patient With MDS and Iron Overload

Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.

Copyright © 2010, Research To Practice, All rights reserved. Part I: Myelodysplastic Syndromes/ Acute Myeloid Leukemia Monday, September 20, :30.

Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.

Final Results From a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Sekeres MA.

What about stem cell transplantation? Dr Catherine Flynn Consultant Haematologist St James’s Hospital 17/06/2011.

Case Study MICR Hematology Spring, 2011 Case # 6 Monique Quiroz Mike Pehl Andrew Ho.

Copyright © 2011, Research To Practice, All rights reserved. National Patterns of Care Study in Breast Cancer Launched October US-based community.

LIBYAN EXPERIENCE IN PEDIATRIC ACUTE MYELOID LEUKEMIA Fathia El Riani, Rasem Al Ajnef, Elham Sbita, Salem Zarroug Departement of pediatric hematology-oncology.

5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].

Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 24, 2004.

Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.

CB-1 MDS Classification and Prognosis John M. Bennett, MD University of Rochester Medical Center Hematomorphologist Chair, MDS Foundation.

Incidence of Hypophosphatemia Phos (Low) Number of Subjects (%) Total N = 511 Grade (55) Grade 1 36 (7) Grade (20) Grade 3 80 (16) Grade 4.

Lenalidomide (REVLIMID ® ) Celgene Corporation New Drug Application (021880) Oncology Drug Advisory Committee Sept 14, 2005 Lenalidomide Review Team Division.

Pei Lin Professor of Pathology Department of Hematopathology

Single-Agent Lenalidomide Induces Complete Remission of Acute Myeloid Leukemia in Patients with Isolated Trisomy 13 Fehniger TA et al. Blood 2009;113(5):

TREATMENT IRON DEFICIENCY ANEMIA. 3 Approaches in the Treatment of IDA: 1.Red Cell Transfusion 2.Oral Iron Therapy 3.Parenteral Iron Therapy Braunwald.

Best of ASH 2007 Myelodysplastic Syndromes Lloyd E. Damon, MD.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Michel Attal, M.D., Valerie Lauwers-Cances, M.D., Gerald Marit, M.D., Denis Caillot, M.D., Philippe Moreau, M.D., Thierry Facon, M.D., Anne Marie Stoppa,

Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.

ANCO 2006 ASH UPDATE MDS Joseph M. Tuscano, M.D. UC Davis Cancer Center.

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.

Is the early cyclosporine A level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia? Eur J Haematol Feb. R2 이 홍 주.

Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.

Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.

MLAB Hematology Keri Brophy-Martinez

Patient history 70 year-old male with macrocytic anemia for 10 years, became transfusion dependent. Splenectomy for refractory anemia: 670gm B12, folate,

Multiple choice questions

Myelodysplastic Syndromes

Myelodysplastic syndrome(MDS)

Azacitidine 75 mg/m2 per day x 7 days q28

Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*

National Patterns of Care Study October 2009

Resistance in the land of molecular cancer therapeutics

by Christopher Dittus, and Dana Semmel

Kantarjian H et al. Cancer 2009;[Epub ahead of print].

Chronic Leukemia Kristine Krafts, M.D..

Fenaux P et al. Lancet Oncol 2009;10(3):

Case:2 leukemia دينا نعمان جرادة جيهان ايمن مقاط.

A young patient with multiple myeloma

Myelodysplastic Syndromes

MDS: Introduction. Supportive Care in the Treatment of Lower-Risk Myelodysplastic Syndromes.

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

by Tahereh Dadfarnia, and Stephen Lee

MYELODYSPLASTIC SYNDROME: prognosis & treatment options

Pollyea DA et al. Proc ASCO 2011;Abstract 6505.

Male patient of 52 years old with a two-year history of fatigue and pruritus of his legs , headache . And visual disturbances . He smoked one pack of.

Toxic Effects Associated With Consumption of Zinc

ASH Review 2018: Update on Myelodysplastic Syndrome

Kantarjian HM et al. Blood 2008;112:Abstract 635.

Presentation transcript:

Copyright © 2009 Research To Practice. All rights reserved. National Patterns of Care Study October Randomly Selected US-based Medical Oncologists in Practice

Copyright © 2009 Research To Practice. All rights reserved. In the past year, how many patients have you seen with the following hematologic cancers? Copyright © 2009 Research To Practice. All rights reserved.

CASE 1 A 78-year-old man WBC /mm 3, Hgb 8.8 g/dL, Hct 25.7%, platelets 87,000/μL Bone marrow biopsy: MDS, no excess blasts Normal cytogenetics and FISH

Copyright © 2009 Research To Practice. All rights reserved. What is this patient’s IPSS classification? Copyright © 2009 Research To Practice. All rights reserved.

What is this man’s estimated survival with no active treatment? (supportive care only) Copyright © 2009 Research To Practice. All rights reserved.

What is this man’s estimated survival with conventional systemic therapy? Copyright © 2009 Research To Practice. All rights reserved.

CASE 1 continued Copyright © 2009 Research To Practice. All rights reserved. Patient chose observation Platelet count ↓ 50,000/μL Became RBC transfusion dependent Received darbepoetin, no response, platelet count ↓ 30,000/μL

Copyright © 2009 Research To Practice. All rights reserved. Which treatment would you recommend at this time?

Copyright © 2009 Research To Practice. All rights reserved. CASE 1 (continued) Copyright © 2009 Research To Practice. All rights reserved. Administered azacitidine 75 mg/m 2 /d SQ x 5 days q4wk Transfusion independent after 4 cycles Hgb 9.5 g/dL, platelet count 50,000/μL

Copyright © 2009 Research To Practice. All rights reserved. How much longer would you recommend that the azacitidine be continued? Copyright © 2009 Research To Practice. All rights reserved.

Administered azacitidine 75 mg/m 2 /d SQ x 5 days q4wk Transfusion independent after 4 cycles Hgb 9.5 g/dL, platelet count 50,000/μL At this time, would you increase the dosing interval?

Copyright © 2009 Research To Practice. All rights reserved. CASE 2 Copyright © 2009 Research To Practice. All rights reserved. A 93-year-old man treated for MDS Received 28 units of packed RBC Hgb 8.0 g/dL, WBC normal, platelet count 109,000/μL Bone marrow biopsy: Hypercellularity, increased iron Chromosomes: del(5)(q15q33)

Copyright © 2009 Research To Practice. All rights reserved. After how many units of packed RBCs do you become concerned about iron overload? ____ units Copyright © 2009 Research To Practice. All rights reserved.

Do you routinely check erythropoietin levels in patients diagnosed with MDS? Copyright © 2009 Research To Practice. All rights reserved.

At what ferritin level do you routinely start iron chelation therapy? ______ µg/dL Copyright © 2009 Research To Practice. All rights reserved.

Which treatment would you recommend for this patient at this time?

Copyright © 2009 Research To Practice. All rights reserved. Continue lenalidomide at a reduced dose of 5 mg daily10% Hold lenalidomide until platelets > 50,000/μL and ANC > 1,000/mm 3, then resume lenalidomide at 10 mg daily 10% Hold lenalidomide until platelets > 50,000/μL and ANC > 1,000/mm 3, then resume lenalidomide at 5 mg daily 74% Discontinue lenalidomide6% Patient receiving lenalidomide 10 mg daily After 2 wks platelets ↓13,000/μL, ANC less than 200/mm 3 Which treatment strategy would you likely recommend?

Copyright © 2009 Research To Practice. All rights reserved. Which treatment would you recommend if this 93-year-old patient experienced intolerance or progressive disease on or after lenalidomide? Copyright © 2009 Research To Practice. All rights reserved.